



# Development, Validation, and Qualification of Novel Clinical Endpoints

---

Chairs:

Sonya Eremenco, MA

Adam Butler

# Disclosures

Sonya Eremenco: Critical Path Institute is supported by the Food and Drug Administration (FDA) of the Department of Health and Human Services (HHS) is 43% funded by the FDA/HHS, totaling \$20,724,703, and 57% funded by non-government source(s), totaling \$27,346,613. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement by, FDA/HHS or the U.S. Government. PRO Consortium is supported by membership fees paid by PRO Consortium member firms. US FDA has provided grants and Broad Agency Announcement contract payments made to the Critical Path Institute beginning September 2019. Grants specifically related to the presentation include 1U01FD008424 and 1U01FD006997.

Adam Butler: Ametris, Signant Health, Cambridge Cognition, Brooklyn Health, Slope AI.



## Speakers

Marc Aafjes, MBA, MS, MSc

Michelle Campbell, PhD

Emma C.

Scott Woods, MD

Sonya Eremenco, MA

Adam Butler